Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4 publications
Exceptional response to FOLFIRINOX in a patient with pancreatic cancer and a germline RAD51C mutation.
Journal: Journal of gastrointestinal oncology
Published: August 29, 2018
Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX.
Journal: Anticancer research
Published: May 14, 2018
The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma.
Journal: Journal of gastrointestinal oncology
Published: March 23, 2018
Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma.
Journal: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
Published: February 01, 2015
Showing 1-4 of 4
Last Updated: 09/26/2026